Formatech fills for Phase I Cellceutix study

Drug formulator Formatech of Andover, MA, will prep Kevetrin, a candidate for the treatment of drug-resistant cancers, for a Cellceutix Phase I study. The small-molecule substance will take the form of a lyophilized powder for reconstitution in saline solution. Terms were not disclosed. Formatech also runs the Fillanthropy program, through which Tracon Pharma recently received an aseptic fill and finish donation for one lot of its TRC102 cancer treatment candidate. Cellceutix release | Tracon announcement

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.